Fig. 1. Comparison of cumulative survival rates of poor outcomes based on the administration of rituximab. Among five poor outcomes during the follow-up period, patients receiving rituximab exhibited a significantly lower cumulative relapse-free survival rate than those compared to receiving rituximab. ESRD, end-stage renal disease; CVA, cerebrovascular accident, ACS, acute coronary syndrome.